Trials / Conditions / wAMD
wAMD
5 registered clinical trials studyying wAMD — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Effica NCT06683742 | EyePoint Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Effic NCT06668064 | EyePoint Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD NCT05407636 | AbbVie | Phase 3 |
| Enrolling By Invitation | Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD NCT05210803 | AbbVie | — |
| Recruiting | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One NCT04704921 | AbbVie | Phase 2 / Phase 3 |